Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients

Documenti analoghi

• Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
  di: Giagounidis, Aristoteles, et al.
  Pubblicazione: (2013)
• Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
  di: Giagounidis, Aristoteles, et al.
  Pubblicazione: (2008)
• The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
  di: Sekeres, Mikkael A., et al.
  Pubblicazione: (2018)
• Recent frustration and innovation in myelodysplastic syndrome
  di: Platzbecker, Uwe, et al.
  Pubblicazione: (2016)
• Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes
  di: Giagounidis, Aristoteles A N, et al.
  Pubblicazione: (2007)